Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

50.9K
Overview
50.9K
Leaky Scanning02:28

Leaky Scanning

5.5K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial.

Nature medicine·2026
Same author

Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D Vaccine.

The American journal of tropical medicine and hygiene·2026
Same author

Human Coronavirus HKU1 Neutralizing Monoclonal Antibodies Target Diverse Epitopes Within and Around the TMPRSS2 Receptor Binding Site.

bioRxiv : the preprint server for biology·2025
Same author

Structural convergence and water-mediated substrate mimicry enable broad neuraminidase inhibition by human antibodies.

Nature communications·2025
Same author

Host RhoA Signaling Controls Filamentous vs. Spherical Morphogenesis and Cell-to-Cell Spread of RSV via Lipid Raft Localization: Host-Directed Antiviral Target.

Microorganisms·2025
Same author

Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.

Cell reports·2025

Related Experiment Video

Updated: Dec 25, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.1K

Next-Generation Influenza Vaccines.

Masaru Kanekiyo1, Barney S Graham1

  • 1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

Cold Spring Harbor Perspectives in Medicine
|April 2, 2020
PubMed
Summary
This summary is machine-generated.

Conventional influenza vaccines use outdated technology. Recent advances in immunogen design, delivery, and immune profiling offer promising new options for developing improved influenza vaccines and evaluating their effectiveness.

More Related Videos

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

12.1K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.6K

Related Experiment Videos

Last Updated: Dec 25, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.1K
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

12.1K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.6K

Area of Science:

  • Vaccinology
  • Immunology
  • Biotechnology

Background:

  • Current influenza vaccines rely on technology developed in the 1940s.
  • Significant advancements in vaccine technology have emerged over the last decade.
  • New immune profiling technologies offer improved correlates of protection and biomarkers for vaccine evaluation.

Purpose of the Study:

  • To review recent technological advances in influenza vaccine development.
  • To provide an outlook on future improvements in influenza vaccines.
  • To highlight new methods for evaluating vaccine efficacy.

Main Methods:

  • Review of emerging technologies in immunogen design and delivery.
  • Analysis of advancements in immune profiling techniques.
  • Discussion of next-generation sequencing, antibody discovery, and structure-guided design.

Main Results:

  • Single-cell analysis, high-throughput antibody discovery, and next-generation sequencing are key technologies.
  • Structure-guided immunogen design, nanoparticle display, and improved adjuvants are advancing vaccine development.
  • Enhanced immune profiling provides better biomarkers for vaccine assessment.

Conclusions:

  • Technological innovations promise significantly improved influenza vaccines.
  • Future vaccines will benefit from advanced immunogen design and delivery systems.
  • Precise immune correlates will enable more effective vaccine evaluations.